  Cisatracuronium Besylate section { margin-bottom: 20px; } table { border-collapse: collapse; } table, tr, th, td { border: 1px solid black; } th, td { padding: 0px 8px 0px 8px; text-align: left; vertical-align: top; } h3, p, ol.custom-counter, li { margin: 0px; padding: 0px; } .text-red { color: red; } .text-black { color: black; } ul.custom-dash { list-style: none; padding-left: 0; margin: 0; } ul.custom-dash > li { display: flex; align-items: flex-start; } ul.custom-dash > li::before { content: "–"; margin-right: 0.5em; flex-shrink: 0; line-height: 1; } ul.custom-dash > li > \*:not(::before) { flex: 1; } ul.custom-dash > li.no-dash::before { content: ""; width: 1em; margin-right: 0.5em; flex-shrink: 0; } /\* Change the ol style \*/ ol.custom-counter { list-style: none; padding-left: 0; counter-reset: custom calc(var(--start, 1) - 1); } ol.custom-counter li { counter-increment: custom; margin-bottom: 5px; } ol.custom-counter li::before { content: counter(custom) ") "; } /\* This is just for this file \*/ ul.custom-bullet-arrow { list-style: none; padding-left: 0; margin: 0; } ul.custom-bullet-arrow > li { display: flex; align-items: flex-start; } ul.custom-bullet-arrow > li::before { content: "↑"; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet-arrow > li.no-arrow::before { content: ""; width: 0.5em; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet\_arrow ul { list-style-type: disc; padding-left: 1.5em; margin-top: 0.5em; } img.resized-200 { width: 200px; height: auto; } img.resized-400 { width: 400px; height: auto; } img.resized-600 { width: 600px; height: auto; } .mb-10px { margin-bottom: 10px; } .mb-20px { margin-bottom: 20px; } .mt-10px { margin-top: 10px; } .mt-20px { margin-top: 20px; } .reference-notes { font-size: 11px; } .text-indent-45px { text-indent: 45px; } .text-bold { font-weight: bold; } .text-center { text-align: center; }

### Vecuronium Bromide, Norcuron

**Acetylcholine:** ACh

**Non-Depolarizing Neuromuscular Blocker:** NDMB

**The ED90:** The effective dose required to produce a specific therapeutic effect in 90% of the population or test subjects

<table><tbody><tr><th>Class</th><td><p>NDMB (Aminosteroid) 2nd Gen.</p><p>Intermediate acting</p></td></tr><tr><th>Subclass</th><td><p>Aminosteroid -monoquaternary</p></td></tr><tr><th>Quick notes</th><td><p>Monoquaternary homolog of pancuronium</p><p>See more notes at the bottom.</p></td></tr><tr><th>Indications</th><td><p>To facilitate endotracheal intubation and to provide skeletal<br>muscle relaxation during surgery or mechanical ventilation</p></td></tr><tr><th>Action</th><td><p>Binds to nicotinic cholinergic receptors, competitively blocks<br>the action of ACh at the postjunctional motor endplate.</p><p>Depolarization is prevented, calcium ions are not released, and<br>muscle contraction does not occur.</p></td></tr><tr><th>Onset</th><td><p>2-3 minutes</p></td></tr><tr><th>Clinical duration</th><td><p>20-50 minutes</p></td></tr><tr><th>Enhance duration</th><td><p>Inhalation agents, certain neuromuscular diseases.</p><p>&gt; 65, liver failure, and cholestasis</p><p>High doses of certain antibiotics</p><p>Magnesium salts for toxemia during pregnancy</p><p>See the list at the bottom of the page.</p></td></tr><tr><th>Decrease duration</th><td></td></tr><tr><th>Dosing</th><td><p><b>IV induction:</b> 0.1mg/kg</p><p>0.08 to 0.1 mg/kg (1.4 to 1.75 times the ED90)</p></td></tr><tr><td><p class="text-bold">Maintenance</p><p>(redose)</p></td><td><p><b>% of intubating dose:</b> 10%</p><p><b>Other literature:</b> 1/3 dose (2-3 mg) or 0.01 to 0.015 mg/kg</p></td></tr><tr><th>Infusion dose</th><td><p>1-2 mcg/kg/min titrate to 1-2 twitches</p></td></tr><tr><th>Diluent for infusion</th><td><p>1 mg/mL</p></td></tr><tr><th>Histamine release</th><td><p>No, some literature states minimal</p></td></tr><tr><th>Side effects</th><td><p>Vagal block with large doses</p></td></tr><tr><th>Metabolism</th><td><p>100%</p><p>Minimal Hepatic metabolism</p><p>Excreted unchanged</p></td></tr><tr><th>Metabolite</th><td><p>3-desacetyl vecuronium, rarely detected following</p><p>prolonged infusion in the I.C.U</p><p>Recovered in urine</p><p>60% potency of vecuronium</p></td></tr><tr><th>Protein bound</th><td><p>60-80% to plasma protein</p></td></tr><tr><th>Pregnancy<br>category</th><td><p>C drug</p><p>Has been used safely for C-sections</p></td></tr><tr><th>Breast feed</th><td><p>As soon as the mother is awake</p><p>It also has poor oral absorption</p></td></tr><tr><th>pH</th><td><p>4</p></td></tr><tr><th>Incompatible with</th><td><p>Alkaline solutions like barbiturates-thiopental</p></td></tr><tr><th>Contraindications</th><td><p>Hypersensitivity to it</p></td></tr><tr><th>Warnings</th><td><p>Patients with neuromuscular diseases</p><p>Possible profound effects. Start with a smaller dose</p></td></tr><tr><th>Reversal agents</th><td><p>Sugammadex, neostigmine, edrophonium, or pyridostigmine</p></td></tr><tr><th>Elimination ½ life</th><td><p>65-75 minutes</p><p><b>In late pregnancy:</b> 35-40 minutes</p><p><b>Renal impairment:</b> Mild increase</p><p><b>Hepatic impairment:</b> Significant increase</p></td></tr><tr><th>Distribution ½ life</th><td><p><b>After IV induction dose:</b> 4 minutes</p></td></tr><tr><th>Route of elimination</th><td><p>Excretion-unchanged</p><p><b>Hepatic-bile:</b> 30-75%</p><p><b>Renal:</b> 10-50%</p></td></tr><tr><th>Adverse reactions</th><td>Anaphylaxis-rare</td></tr><tr><th>Vol of distribution</th><td>300 to 400 mL/kg</td></tr><tr><th>ED<sub>95</sub> Potency (mg/kg)</th><td>0.05</td></tr><tr><th>Recovery Index<br>(RI 25-75) mins</th><td>10-25</td></tr><tr><th>Compatible solutions</th><td>Dextrose Injection 5%, NS, Dextrose (5%) Injection, and NaCl or LR.</td></tr><tr><th>Storage</th><td>In a lyophilized powder at room temperature</td></tr></tbody></table>

-   Vecuronium is simply pancuronium without the quaternizing methyl group in the 2-peridino substitution.
-   More potent with shorter duration than pancuronium

Vecuronium vs Pancuronium

-   1/3 more potent than Pancuronium
-   Does not have vagolytic properties of pancuronium at a normal dose
-   More lipid solubility

Possible adverse effects:

Prolonged paralysis (seen in long-term use)

-   Respiratory depression
-   Apnea
-   Anaphylaxis/hypersensitivity reaction

Can a patient have an allergic reaction with their first exposure to vecuronium?

**Answer:** Yes

-   An allergic reaction from the first exposure to vecuronium would suggest a prior sensitization to a compound within vecuronium.
-   A study suggests that repetitive exposure to quaternary ammonium compounds used in hairdressing is a risk factor for sensitization to certain muscle relaxants.
-   Hairdressers are routinely exposed to a wide range of hair products containing the quaternary ammonium compound.
-   This repeated exposure to quaternary ammonium compounds can lead to the development of IgE antibodies specific.
-   Vecuronium contains a quaternary ammonium.
-   After the administration of vecuronium, the quaternary ammonium can act as an antigenic epitope, triggering an immune response in sensitized individuals and possibly an anaphylactic reaction.
-   One study showed that 7.4% of hairdressers had IgE antibodies to quaternary ammonium, compared to only 1.6% of non-hairdressing apprentices.

Other less common adverse events include:

-   Hypotension
-   Edema
-   Sinus tachycardia
-   Erythema
-   Urticaria
-   Flushing
-   Pruritus
-   Skin rash

High doses of antibiotics that increase the duration of vecuronium:

Aminoglycosides:

-   kanamycin
-   gentamicin
-   neomycin
-   streptomycin
-   dihydrostreptomycin

Other antibiotics

-   bacitracin
-   tetracyclines
-   colistin
-   polymyxin B

Other factors that increase the duration of nondepolarizing muscle relaxants:

-   Cardiac antidysrhythmic drugs
-   Diuretics
-   Local anesthetics-amides
-   HYPOkalemia
-   Respiratory acidosis
-   Hypothermia
-   Ca channel blockers
-   Ketamine
-   Lithium
-   Immunosuppressants
-   Hepatic disease
-   Neuromuscular diseases

Factors that can decrease the duration of nondepolarizing muscle relaxants:

-   Increased plasma levels of pseudocholinesterase (butyrylcholinesterase)
-   Obesity (increased volume of distribution)
-   HYPERkalemia
-   Alkalosis
-   Inflammation
-   Cancer and its treatments
-   Burns > 30%- from upregulation of acetylcholine receptors (AChRs)
-   Prolonged immobility, from upregulation of AChRs
-   Aminophylline
-   Steroids
-   Dilantin (phenytoin)
-   CVA- from upregulation of AChRs

Barash, Cullen, and Stoelting’s Clinical Anesthesia, 9th Ed, 2024

CH. 21, Neuromuscular Blocking Drugs; p. 512

Wade A. Weigel, Stuard Alan Grant, and Stephen R. Thilen

Morgan & Mikhail’s Clinical Anesthesiology 7th Ed., 2022

CH.11, Neuromuscular Blocking Agents, p. 202-208, 210-212

Vecuronium bromide for the injection of Clinical Pharmacology

Pfizer Medical (accessed 09/20245)

https://www.pfizermedical.com/vecuronium-bromide/clinical-pharmacology

Vecuronium

DrugBank (accessed 09/2025)

https://go.drugbank.com/drugs/DB01339

Vecuronium

NIH (National Library of Medicine)

StatPearls (accessed 09/2025)

Preeti Patel; Russell K. and McAllister

https://www.ncbi.nlm.nih.gov/books/NBK493143/

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6th Ed, 2022

CH. 12 Neuromuscular-Blocking Drugs and Reversal Agents, pp. 319

Pamela Flood, James P. Rathmell

Prevalence of IgE against neuromuscular blocking agents in hairdressers and bakers

Clinical & Experimental Allergy, 2013;43:1256-1262

Dong S, Acouetey DS, Guéant-Rodriguez R-M, Zmirou-Navier D, Rémen T, Blanca M, Mertes PM, Guéant J-L